Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California.
Biol Blood Marrow Transplant. 2020 Jan;26(1):189-196. doi: 10.1016/j.bbmt.2019.08.022. Epub 2019 Sep 5.
Allogeneic hematopoietic cell transplantation (alloHCT) has been increasingly offered to older adults with hematologic malignancies. However, optimal methods to determine fitness for alloHCT have yet to be defined. We evaluated the ability of a comprehensive geriatric assessment (CGA) to predict post-alloHCT outcomes in a single-center prospective cohort study of patients age 50 years and older. Outcomes included overall survival (OS), progression-free survival (PFS), and nonrelapse mortality (NRM). A total of 148 patients were included, with a median age of 62 years (range, 50 to 76 years). In multivariate regression analysis, several CGA measures of functional status were predictive of post-alloHCT outcomes, after adjusting for traditional prognostic factors. Any deficit in instrumental activities of daily living (IADL) was associated with inferior OS (hazard ratio [HR], 1.81, 95% confidence interval [CI], 1.07 to 3.08; P = .03) and PFS (HR, 1.85; 95% CI, 1.15 to 2.99; P = .01). A Medical Outcomes Study Physical Health scale (MOS-PH) score <85 was associated with inferior OS (HR, 1.96; 95% CI, 1.13 to 3.40; P = .02), PFS (HR, 1.75; 95% CI, 1.07 to 2.88; P = .03), and increased NRM (subdistribution HR, 2.57; 95% CI, 1.12 to 5.92; P = .03). MOS-PH score was also associated with the number of non-hematologic grade ≥3 adverse events within the first 100 days after alloHCT (rate ratio, 1.61; 95% CI, 1.04 to 2.49; P = .03). These findings support previous work suggesting that IADL is an important prognostic tool prior to alloHCT. MOS-PH is newly identified as an additional metric to identify older patients at higher risk of poor post-alloHCT outcomes, including toxicity and NRM.
异基因造血细胞移植(alloHCT)已越来越多地用于老年血液系统恶性肿瘤患者。然而,确定 alloHCT 适宜性的最佳方法尚未确定。我们评估了综合老年评估(CGA)在单中心前瞻性队列研究中预测 50 岁及以上患者 alloHCT 后结局的能力。结局包括总生存(OS)、无进展生存(PFS)和非复发死亡率(NRM)。共纳入 148 例患者,中位年龄 62 岁(范围 50 至 76 岁)。在多变量回归分析中,调整传统预后因素后,几项 CGA 功能性状态测量指标与 alloHCT 后结局相关。任何日常生活活动(IADL)的缺陷与较差的 OS(风险比[HR],1.81,95%置信区间[CI],1.07 至 3.08;P =.03)和 PFS(HR,1.85;95% CI,1.15 至 2.99;P =.01)相关。医学结局研究身体健康量表(MOS-PH)评分<85 与较差的 OS(HR,1.96;95% CI,1.13 至 3.40;P =.02)、PFS(HR,1.75;95% CI,1.07 至 2.88;P =.03)和增加的 NRM(亚分布 HR,2.57;95% CI,1.12 至 5.92;P =.03)相关。MOS-PH 评分也与 alloHCT 后 100 天内非血液学≥3 级不良事件的数量相关(率比,1.61;95% CI,1.04 至 2.49;P =.03)。这些发现支持先前的工作,表明 IADL 是 alloHCT 前重要的预后工具。MOS-PH 是新确定的另一个指标,用于识别 alloHCT 后结局较差(包括毒性和 NRM)风险较高的老年患者。